神经内分泌肿瘤治疗市场规模、份额和成长分析（按肿瘤类型、治疗产品、部位、最终用途和地区划分）—产业预测（2026-2033 年）

全球神经内分泌肿瘤治疗市场预计到 2024 年将达到 24.8 亿美元，到 2025 年将达到 26.2 亿美元，到 2033 年将达到 41.1 亿美元，预测期（2026-2033 年）的复合年增长率为 5.8%。

神经内分泌肿瘤（NETs）通常起源于神经细胞或内分泌细胞，其在全球范围内的发生率正在上升。类癌尤其常见于胃肠道、阑尾、直肠、胰臟和肺部。这些肿瘤可表现为良性或恶性，并可引起多种症状，包括消化器官系统问题、慢性咳嗽和心血管疾病。由于研发投入的增加、创新治疗方法的推出以及能够实现早期检测的诊断技术的进步，神经内分泌肿瘤治疗市场预计将迎来显着增长。这些因素共同推动了市场的动态，并为全球患者提供了更多有效的治疗选择。

全球神经内分泌肿瘤治疗驱动因素

全球神经内分泌肿瘤治疗市场受到全球神经内分泌肿瘤（NETs）发生率和盛行率不断上升的显着影响。随着越来越多的患者被诊断出患有这种罕见疾病，对有效治疗方法的需求也日益增长。这种日益增强的认知和不断上升的发病率推动了NET特异性药物的问世，从而促进了市场成长。因此，治疗方法满足患者的需求，创新和标靶治疗的需求日益迫切，这正在重塑市场格局，并推动神经内分泌肿瘤治疗市场的发展，因为医疗服务提供者正在努力应对这一紧迫的医疗挑战。

限制全球神经内分泌肿瘤治疗市场的因素

全球神经内分泌肿瘤治疗市场的成长可能面临重大挑战，原因在于开发有效治疗方法的高成本以及这些疗法可能带来的副作用。接受治疗的患者可能会出现多种不良反应，包括血糖值升高、胆结石形成以及胃肠道疾病（如腹胀和噁心）。这些因素可能导致患者和医疗服务提供者在选择这些治疗方法时犹豫不决，从而影响市场动态，并限制该行业在满足未被满足的需求方面的整体扩张。应对这些挑战对于市场的未来发展至关重要。

全球神经内分泌肿瘤治疗市场趋势

全球神经内分泌肿瘤治疗市场正经历显着成长，其中生长抑制素类似物（SSA）已成为领先的治疗选择。这些药物因其能有效抑制肿瘤生长、缓解症状并作为可靠的生物标记物，已成为许多患者的首选治疗方法。 SSA凭藉其安全性和有效性，尤其适用于不适合放射线治疗或手术的患者，已占据可观的市场份额。此外，正在进行的临床试验以及新型SSA製剂的核准将进一步巩固其市场地位，展现出神经内分泌肿瘤治疗领域蓬勃发展的市场格局。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术分析
• 监管分析
• 专利分析
• 案例研究

全球神经内分泌肿瘤治疗市场规模（按肿瘤类型和复合年增长率划分）（2026-2033 年）

• 脑膜瘤
• 肾上腺癌
• 类癌肿瘤
• 副神经节瘤
• 嗜铬细胞瘤
• 其他的

全球神经内分泌肿瘤治疗市场规模（依治疗产品划分）及复合年增长率（2026-2033 年）

• 生长抑制素类似物（SSA）
• 标靶治疗
• 其他的

全球神经内分泌肿瘤治疗市场规模（按部位和复合年增长率划分）（2026-2033 年）

• 肺
• 胰臟
• 冒号
• 小肠
• 直肠
• 胃
• 其他的

全球神经内分泌肿瘤治疗市场规模（按最终用途和复合年增长率划分）（2026-2033 年）

• 医院
• 诊所
• 其他的

全球神经内分泌肿瘤治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Novartis AG（Switzerland）
• Bristol Myers Squibb Company（US）
• Pfizer Inc.（US）
• Boehringer Ingelheim International GmbH（Germany）
• Hutchison MediPharma Limited（China）
• AVEO Pharmaceuticals, Inc.（US）
• Ipsen Pharma（France）
• Eli Lilly and Company（US）
• Exelixis, Inc.（US）
• Jubilant Pharmova Limited（India）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Viatris Inc.（US）
• Thermo Fisher Scientific Inc.（US）
• Regeneron Pharmaceuticals, Inc.（US）
• Sun Pharmaceutical Industries Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Lupin（India）
• Exact Sciences Corporation（US）
• Advanced Accelerator Applications（France）
• BioSynthema Inc.（US）

结论与建议

Global Neuroendocrine Tumors Treatment Market size was valued at USD 2.48 Billion in 2024 and is poised to grow from USD 2.62 Billion in 2025 to USD 4.11 Billion by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The global prevalence of neuroendocrine tumors (NET), often arising from neurological and endocrine cells, is on the rise, with carcinoid tumors predominantly found in the gastrointestinal tract, as well as the appendix, rectum, pancreas, and lungs. These tumors may present as benign or malignant and can lead to various symptoms, including gastrointestinal issues, chronic coughing, and cardiovascular problems. The market for neuroendocrine tumor treatments is poised for substantial growth, driven by increased research and development investments, the introduction of innovative therapies, and advancements in diagnostic techniques that facilitate early detection. This combination of factors contributes to enhanced market dynamics and the proliferation of effective treatment options for patients globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neuroendocrine Tumors Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neuroendocrine Tumors Treatment Market Segments Analysis

Global Neuroendocrine Tumors Treatment Market is segmented by Tumor Types, Treatment Products, Sites, End Uses and region. Based on Tumor Types, the market is segmented into Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma, Pheochromocytoma and Others. Based on Treatment Products, the market is segmented into Somatostatin Analogs (SSAs), Targeted Therapy and Others. Based on Sites, the market is segmented into Lung, Pancreas, Colon, Small Intestine, Rectum, Stomach and Others. Based on End Uses, the market is segmented into Hospitals, Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neuroendocrine Tumors Treatment Market

The Global Neuroendocrine Tumors Treatment market is significantly influenced by the increasing incidence and prevalence of neuroendocrine tumors (NET) across the globe. As more individuals are diagnosed with this rare condition, there is a growing demand for effective treatment options. This heightened awareness and incidence drive the adoption of medications specifically designed for NET, contributing to market growth. The result is a rising urgency for innovative therapies and targeted treatments that cater to the needs of patients, ultimately shaping the landscape of the neuroendocrine tumors treatment market and fueling its advancement as healthcare providers seek to address this pressing medical challenge.

Restraints in the Global Neuroendocrine Tumors Treatment Market

The growth of the Global Neuroendocrine Tumors Treatment market is likely to face significant challenges due to the substantial costs associated with developing effective therapies and the potential side effects linked to these treatments. Patients undergoing treatment may experience various adverse effects, such as elevated blood sugar levels, gallstone formation, and gastrointestinal issues like bloating and nausea. These factors could deter both patients and healthcare providers from pursuing these therapies, thereby influencing market dynamics and limiting the overall expansion of the sector in response to unmet medical needs. Addressing these challenges will be crucial for future market development.

Market Trends of the Global Neuroendocrine Tumors Treatment Market

The Global Neuroendocrine Tumors Treatment market is experiencing significant growth, with somatostatin analogs (SSAs) emerging as the leading therapeutic option. These medications effectively manage tumor growth, alleviate symptoms, and serve as reliable biomarkers, making them preferred treatments for many patients. SSAs command a substantial revenue share in the market due to their safety and efficacy, particularly for those not suitable for radiotherapy or surgery. Additionally, the ongoing clinical trials and forthcoming approvals of novel SSA formulations promise to further enhance their market position, indicating a robust and dynamic landscape in neuroendocrine tumor therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Neuroendocrine Tumors Treatment Market Size by Tumor Types & CAGR (2026-2033)

• Market Overview
• Meningiomas
• Adrenal Cancer
• Carcinoid Tumors
• Paraganglioma
• Pheochromocytoma
• Others

Global Neuroendocrine Tumors Treatment Market Size by Treatment Products & CAGR (2026-2033)

• Market Overview
• Somatostatin Analogs (SSAs)
• Targeted Therapy
• Others

Global Neuroendocrine Tumors Treatment Market Size by Sites & CAGR (2026-2033)

• Market Overview
• Lung
• Pancreas
• Colon
• Small Intestine
• Rectum
• Stomach
• Others

Global Neuroendocrine Tumors Treatment Market Size by End Uses & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Others

Global Neuroendocrine Tumors Treatment Market Size & CAGR (2026-2033)

• North America (Tumor Types, Treatment Products, Sites, End Uses)
  • US
  • Canada
• Europe (Tumor Types, Treatment Products, Sites, End Uses)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Tumor Types, Treatment Products, Sites, End Uses)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Tumor Types, Treatment Products, Sites, End Uses)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Tumor Types, Treatment Products, Sites, End Uses)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hutchison MediPharma Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AVEO Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharmova Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Accelerator Applications (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioSynthema Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations